Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MGTA | Common Stock | Award | $2.82K | +3K | +21.03% | $0.94 | 17.3K | Nov 30, 2022 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). |
F2 | In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022. |
Title: Chief Financial and Operating Officer